- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Spectrum Pharmaceuticals, Inc. (SPPI)
by latest | most commented
-
FDA Calendar Updates: Rigel Pharma, GlaxoSmithKline, Eisai, SuperGen
-
FDA Calendar Updates: Oxford, Protalix, Spectrum, Shire
-
Spectrum: FDA News on Zevalin Equals an Approval
-
Spectrum Pharmaceuticals: Temporary Setback
-
Closing Update for Wednesday, July 1
-
Big Lineup of Healthcare Stocks Crack the Russell 3000 Index
-
Can Spectrum Pharmaceuticals Benefit from FDA Action on Zevalin?
-
17 Reasons Why Bayer Might Acquire Spectrum Pharmaceuticals
-
Spectrum Pharmaceuticals: Optimistic About Zevalin's Prospects
-
Today's Healthcare Market Movers: SCLN, HEB, SPPI, CRTX, KV.A
-
Pending FDA Decisions: 20 Extreme Trades
-
15 Possible Healthcare Breakout Stocks
-
Spectrum Pharmaceuticals: Undervalued Growth Company with Strong Late-Stage Pipeline
-
FDA Calendar: 18 Hot Summer Trades
-
Two Possible Upcoming Approvals for Spectrum Pharmaceuticals
-
13 Extreme FDA Trades
-
Pending FDA Decisions: 12 Extreme Trades
-
FDA, Clinical Trial Calendars: Nine 'Cash Plus Catalyst' Trades
-
Cell Therapeutics' Turnaround Remains on Track
-
Vanda Pharma: An Extreme FDA Trade That Paid; 9 More to Go
-
Tracking Cancer Diagnostic and Therapeutic Stocks
-
Cell Therapeutics Reemerging
-
12 Extreme FDA Trades on New Product Decisions
-
FDA and Clinical Trial Updates: Osiris Sees Flaw in Crohn's Disease Trial
-
Trading FDA Decisions: 14 Candidates
-
Chink in the Biotechnology Armor
-
Biotech FDA and Clinical Trial Calendar Update
-
Cell Therapeutics Is down but Not Out
-
Which Has a Better Risk/Reward Ratio - Citigroup or Cell Genesys?
-
Cancer Stocks Finish a Tough Quarter
-
Cancer Stocks: Tracking the Market
-
Cancer Stocks: The Bleeding Slows
-
Cancer Stocks Hammered Once Again
-
Cancer Stocks Slide Again
-
Cancer Stocks Plunge Following ASCO Meeting
-
Cancer Stocks Soar With Annual ASCO Meeting
-
Cancer Stocks on the Go: Winners and Losers
-
Biotech Week in Review: Onyx Is Star of the Week
-
Spectrum Pharmaceuticals, GPC Up Strongly on Positive Phase 3 Trials for Prostate Cancer Drug